Radiation protectants: Current status and future prospects

Health Physics

Volumn 89, Issue 5, 2005, Pages 531-545

  Seed, Thomas M ^a  

^a CATHOLIC UNIVERSITY OF AMERICA   (United States)

Author keywords

Health effects; National Council on Radiation Protection and Measurements; Radiation, ionizing; Terrorism

Indexed keywords

ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; AMIFOSTINE; AMINOTHIOL; ANDROSTENEDIOL; BETAFECTIN; FERRIC FERROCYANIDE; GENISTEIN; GRANISETRON; HYDROXYLAMINE; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 1 RADIOPROTECTIVE DOMAIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MANGANESE SUPEROXIDE DISMUTASE; NEUMUNE; NUTRACEUTICAL; PALIFERMIN; PENTETATE CALCIUM; PENTETATE ZINC; PHOSPHONOL; PHOSPHOROTHIOIC ACID DERIVATIVE; PHOSPHOROTHIOIC ACID S [2 (3 METHYLAMINOPROPYLAMINO)ETHYL] ESTER; POTASSIUM IODIDE; RADIOPROTECTIVE AGENT; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR 20; RECOMBINANT INTERLEUKIN 11; RECOMBINANT MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RECOMBINANT MANGANESE SUPEROXIDE DISMUTASE; RECOMBINANT STEM CELL FACTOR; TEMPOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELAFERMIN;

CHEMICAL ENGINEERING; COMBINATORIAL CHEMISTRY; CONFERENCE PAPER; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG USE; ELECTROMAGNETIC FIELD; GASTROINTESTINAL SYMPTOM; GENE TRANSFER; HEALTH HAZARD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOTENSION; IMMUNOMODULATION; INJECTION SITE REACTION; IONIZING RADIATION; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH; RADIATION EXPOSURE; RADIATION INJURY; RADIATION PROTECTION; SLOW RELEASE FORMULATION; STEM CELL TRANSPLANTATION; TERRORISM;

COMBINATORIAL CHEMISTRY TECHNIQUES; DIETARY SUPPLEMENTS; ELECTROMAGNETIC FIELDS; GENE TRANSFER, HORIZONTAL; GENETIC ENGINEERING; HUMANS; RADIATION INJURIES; RADIATION PROTECTION; RADIATION-PROTECTIVE AGENTS;

EID: 26844492808     PISSN: 00179078     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.HP.0000175153.19745.25     Document Type: Conference Paper

References (99)

1. Alvarez E, Fey EG, Valax P, Yim Z, Peterson JD, Mesri M, Jeffers M, Dindinger M, Twomlow N, Ghatpande A, LaRochelle WJ, Sonis ST, Lichenstein HS. Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis. Clin Cancer Res 9:3454-3461, 2003.
2. Ameirican College for Nuclear Physicians. FDA approves first Prussian blue drug [online]; 2003. Available at: http:// www.acnponline.org. Accessed 1 May 2004.
3. Bardet E, Martin L, Calais G, Tuchais C, Bourhis J, Rhein B, Feham N, Alphonsi M. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of Amifostine for head and neck tumors treated by external radiotherapy. Semin Oncol 29(6 Suppl 19):57-60; 2002.
4. Bonner HS, Shaw LM. New dosing regimens for Amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion. J Clin Pharmacol 42:166-174; 2002.
5. Bourhis J, Rosine D. Radioprotective effect of Amifostine in patients with head and neck squamous cell carcinoma. Semin Oncol 29(6 Suppl 19):61-62; 2002.
6. Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F, Zhang J, Russell L, Oster W, Sauer R. Phase III randomized trial of Amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18:3339-3345; 2000.
7. Brown DQ, Graham WJ, MacKenzie LJ, Pittock JW, Shaw LM. Can WR-2721 be improved upon? Pharmac Ther 39:157-169; 1988.
8. Buckpitt A, Baggot JD, Hietala S, Taylor C, Sagara D, Goldman M. Bioavailability and excretion of the radioprotective agent WR3689 in Rhesus macaques. U.S. Army Medical Research; #DAMD 17-86-C6177, Contract Report; 1988.
9. Carnes BA, Grdina DJ. In vivo protection by the aminothiol WR-2721 against neutron-induced carcinogenesis. Int J Radiat Biol 61:567-576; 1992.
10. Chute JP, Fung J, Muramoto G, Erwin R. Ex vivo culture rescues hematopoietic stem cells with long-term repopulating capacity following harvest from lethally irradiated mice. Exp Hematol 32:308-317; 2004.
11. Coleman CN, Blakely WF, Fike JR, MacVittie TJ, Metting NF, Mitchell JB, Moulder JE, Preston RJ, Ricks RC, Seed TM, Stone HB, Tofilon PJ, Wong RSL. Molecular and cellular biology of moderate-dose (1-10 Gy) radiation and potential mechanisms of radiation protection: Report of a workshop at Bethesda, Maryland, December 17-18, 2001. Radiat Res 159:162-184; 2003.
12. Culy CR, Spencer CM. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 61:641-684; 2001.
13. Dainiak N, Waselenko JK, Armitage JO, MacVittie TJ, Farese AM. The hematologist and radiation casualties. Hematology 2003:473-496; 2003.
14. Davidson DE, Grenan MM, Sweeney TR. Biological characteristics of some improved radioprotectors In: Brady LW, ed. Radiation sensitizers, their use in the clinical management of cancer. Cancer management. New York: Mason; 1980: 309-320.
15. Devi PU. Radioprotective, anticarcinogenic and antioxidant properties of the Indian holy basil, Ocimum sanctum (Tulasi). Indian J Exp Biol 39:185-190; 2001.
16. Devi PU, Ganasoundari A. Radioprotective effect of leaf extract of Indian medicinal plant Ocimum sanctum. Indian J Exp Biol 33:205-208; 1995.
17. Devi PU, Bisht KS, Vinitha M. A comparative study of radioprotection by Ocimum flavonoids and synthetic aminothiol protectors in the mouse. Br J Radiol 71:782-784; 1998.
18. DiCarlo AL, White NC, Litovitz TA. Mechanical and electromagnetic induction of protection against oxidative stress. Bioelectrochem 53:87-95; 2000.
19. Doherty DG, Burnett WT, Shapira R. Chemical protection against ionizing radiation. II. Mercaptoalkylamines and related compounds with protective activity. Radiat Res 7:13-21; 1957.
20. Durand RE, Olive PL. Radiosensitization and radioprotection by BSO and WR-2721: the role of oxygenation. Br J Cancer 60:517-522; 1989.
21. Epperly MW, Bray JA, Kraeger S, Zwacka R, Engelhardt J, Travis E, Greenberger JS. Prevention of late effects of irradiation lung damage by manganese superoxidase dismutase gene therapy. Gene Ther 5:196-208; 1998.
22. Epperly MW, Kagan VE, Sikora CA, Gretton JE, Defilippi SJ, Bar-Sagi D, Greenberger JS. Manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) administration protects mice from esophagitis associated with fractionated radiation. Int J Cancer 96:221-231; 2001.
23. Facorro G, Sarrasague MM, Torti H, Hager A, Avalos JS, Foncuberta M, Kusminsky G. Oxidative study of patients with total body irradiation: effects of Amifostine treatment. Bone Marrow Transplant 33:793-798; 2004.
24. Fang YZ, Yang S, Wu G. Free radicals, antioxidants, and nutrition. Nutrition 18:872-879; 2002.
25. Farese AM, Smith WG, Giri JG, Siegel N, McKearn JP, MacVittie TJ. Promegapoietin-1a, an engineered chimeric IL-3 and Mp1-L receptor agonist, stimulates hematopoietic recovery in conventional and abbreviated schedules following radiation-induced myelosuppression in nonhuman primates. Stem Cells 19:329-338; 2001a.
26. Farese AM, Casey DB, Smith WG, Vigneulle RM, McKearn JP, MacVittie TJ. Leridistim, a chimeric dual G-CSF and IL-3 receptor agonist, enhances multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression: effect of schedule, dose and route of administration. Stem Cells 19:522-533; 2001b.
27. Farrell CL, Bready JV, Rex KL, Chen JN, DiPalma CR, Whitcomb KL, Yin S, Hill DC, Wiemann B, Starnes CO, Havill AM, Lu ZN, Aukerman SL, Pierce GF, Thomason A, Potten CS, Ulich TR, Lacey DL. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 58:933-939; 1998.
28. Fatome M, Courteille F, Laval JD, Roman V. Radioprotective activity of ethylcellulose microspheres containing WR 2721, after oral administration. Int J Radiat Biol Relat Stud Phys Chem Med 52:21-29; 1987.
29. Ferguson CD, Potter WC, Sands A, Specter LS, Wehling FL. The four faces of nuclear terrorism. Monterey, CA: Center for Nonproliferation Studies, Monterey Institute of International Studies; 2004.
30. Freireich EJ, Gehan EA, Rail DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50:219-244; 1966.
31. Grdina DJ, Kataoka Y, Murley JS. Amifostine: mechanisms of action underlying cytoprotection and chemoprevention. Drug Metabol Drug Interact 16:237-279; 2000.
32. Grdina DJ, Murley JS, Kataoka Y, Epperly W. Relationships between cytoprotection and mutation prevention by WR-1065. Mil Med 167(Suppl 1):51-53; 2002.
33. Greenberger JS, Epperly MW, Gretton J, Jefferson M, Nie S, Bernarding M, Kagan V, Guo HL. Radioprotective gene therapy. Curr Gene Ther 3:183-195; 2003.
34. Guo H, Seixas-Silva JA Jr., Epperly MW, Gretton JE, Shin DM, Bar-Sagi D, Archer H, Greenberger JS. Prevention of radiation-induced oral cavity mucositis by plasmid/liposome delivery of the human manganese superoxide dismutase (SOD2) transgene. Radiat Res 159:361-370; 2003.
35. Hahn SM, Krishna MC, Mitchell JB. Stable free radicals as radiation protectors in radioprotection. In: Chemical, biological, and clinical perspectives. Boca Raton, FL: CRC Press; 1997: 111-126.
36. Hahn SM, Krishna MC, DeLuca AM, Coffin D, Mitchell JB. Evaluation of the hydroxylamine Tempol-H as an in vivo radioprotector. Free Radic Biol Med 28:953-958; 2000.
37. Hollis Eden Pharmaceuticals. Products-Neumune [online]. Available at: http://www.holliseden.com. Accessed 25 June 2004.
38. Kehlet RA, Robinson SI, Young RW, Feister A. Selection of a drug for prevention of radiation-induced nausea and vomiting. In: Reeves GI, Jarrett DG, Seed TM, King GL, Blakely WF, eds. Triage of irradiated personnel. Armed Forces Radiobiology Research Institute Workshop. Bethesda, MD: Armed Forces Radiobiology Research Institute; 1996: A7-A12.
39. Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 170:22-48; 2004.
40. Krasil'nikov II. Prospects for improvements of pharmacologic radioprotective agents. Voen Med Zh 322:56-61, 96; 2001.
41. Kumar KS, Vaishnav YN, Smith C, Clark EP. Radiation injury and antioxidant mechanisms of protection. In: Nigam S, Honn KV, Marnett LJ, Walden TL, eds. Eicosanoids and other bioactive lipids in cancer, inflammation and radiation injury. Boston, MA: Kluwer Academic Publishers; 1991: 333-339.
42. Kumar KS, Srinivasan V, Toles R, Seed T. Radioprotection by nutraceuticals-vitamin E, selenium, copper, and zinc. In: Proceedings of the radioprotectors for human health, satellite meeting. Kyoto, Japan: International Society for Radiation Hematology; 2001: 15.
43. Kumar KS, Srinivasan V, Toles R, Jobe L, Seed TM. Nutritional approaches to radioprotection: vitamin E. Mil Med 167(Suppl 2):57-59; 2002.
44. Landauer MR, Davis HD, Dominitz JA, Weiss JF. Dose and time relationships of the radioprotector WR-2721 on locomotor activity in mice. Pharmacol Biochem Behav 27:573-576; 1987.
45. Landauer MR, Davis HD, Kumar KS, Weiss JF. Behavioral toxicity of selected radioprotectors. Adv Space Res 12:273-283; 1992.
46. Landauer MR, Srinivasan V, Seed TM. Genistein treatment protects mice from ionizing radiation injury. J Appl Toxicol 23:379-385; 2003.
47. Lanza R, Rosenthal N. The stem cell challenge. Sci Am (June):92-99; 2004.
48. Lee TK, Stupans I. Radioprotection: the non-steroidal antiinflammatory drugs (NSAIDs) and prostaglandins. J Pharm Pharmacol 54:1435-1445; 2002.
49. Lord BI, Marshall E, Woolford LB, Hunter MG. BB-10010/ MIP-1 alpha in vivo maintains haemopoietic recovery following repeated cycles of sublethal irradiation. Br J Cancer 74:1017-1022; 1996.
50. Maisin JR. Chemical protection against ionizing radiation. Adv Space Res 9:205-212; 1989.
51. Maisin JR. Bacq and Alexander Award lecture: chemical radioprotection: past, present, and future prospects. Int J Radiat Biol 73:443-450; 1998.
52. Manola KN, Terzoudi GI, Dardoufas CE, Malik SI, Pantelias GE. Radioprotective effect of Amifostine on cells from cancer prone patients and healthy individuals studied by the G2 and PCC assays. Int J Radiat Biol 79:831-838; 2003.
53. Marzatico F, Porta C, Moroni M, Bertorelli L, Borasio E, Finotti N, Pansarasa O, Castagna L. In vitro antioxidant properties of Amifostine (WR-2721, Ethyol). Cancer Chemother Pharmacol 45:172-176; 2000.
54. MedImmune [online]. Available at: http://www.medimmune. com/products/ethyol/index.asp. Accessed 1 April 2004.
55. Mitchell JB, Krishna MC. Nitroxides as radiation protectors. Mil Med 167(Suppl 1):49-50; 2002.
56. Mitchell JB, Samuni Krishna MC. Biologically active metal-independent superoxide dismutase mimics. Biochem 29:2802-2807; 1990.
57. Murley JS, Kataoka Y, Cao D, Li JJ, Oberley LW, Grdina DJ. Delayed radioprotection by NF-kappa B-mediated induction of Sod2 (MnSOD) in SA-NH tumor cells after exposure to clinically useful thio-containing drugs. Radiat Res 162:536-546; 2004.
58. Na Nakorn T, Traver D, Weissman IL, Akashi K. Myeloerythroid-restricted progenitors are sufficient to confer radioprotection and provide the majority of day 8 CFU-S. J Clin Invest 109:1579-1585; 2002.
59. Nair CK, Panda DK, Nomura T. Radioprotectors in radiotherapy. J Radiat Res (Tokyo) 42:21-37; 2001.
60. Neta R. Modulation with cytokines of radiation injury: suggested mechanisms of action. Environ Health Perspect 105(Suppl 6):1463-1465; 1997.
61. Paio A, Crespo RF, Seneci P, Ciraco M. Solid-supported benzotriazoles. 2. Synthetic auxiliaries and traceless linkers for the combinatorial synthesis of unsymmetrical ureas. J Comb Chem 3:354-359; 2001.
62. Pamujula S, Graves RA, Freeman T, Srinivasan V, Bostanian LA, Kishore V, Mandal TK. Oral delivery of spray dried PLGA/Amifostine nanoparticles. J Pharm Pharmacol 56:1119-1125; 2004.
63. Patchen ML, MacVittie TJ, Solberg BD, D'Alesandro MM, Brook I. Radioprotection by polysaccharides alone and in combination with aminothiols. Adv Space Res 12:233-248; 1992.
64. Pellmar TC, Rockwell S, and the Radiological/Nuclear Threat Countermeasure Working Group. Meeting report: priority list of research areas for radiological nuclear threat countermeasures. Radiat Res 163:115-123; 2005.
65. Radiation Emergency Assistance Center/Training Site. REAC/TS [online]. Available at: http://www.orau.gov/ reacts. Accessed 4 June 2004.
66. Riklis E. Radioprotection of DNA by biochemical mechanisms. Adv Space Res 12:209-212; 1992.
67. Seed TM, Inal C, Deen J, Ramakrishnan N. Damage and repair of sublethally irradiated hematopoietic progenitors. In: Moriarty M, Mothersill C, Seymour C, eds. Radiation research, 11th ICRR. Lawrence, KS: Allen Press; 1999: 93.
68. Seed TM, Blakely WF, Knudson GB, Landauer MR, McClain DE, eds. Low-level radiation injury and medical countermeasures. Proceedings of the international conference on low-level radiation injury and medical countermeasures. Mil Med 167(Suppl 1); 2002a: 1-143.
69. Seed TM, Fry SA, Neta R, Weiss JF, Jarrett DG, Thomassen D. Prevention and treatments: summary statement. Mil Med 167(Suppl 2):87-93; 2002b.
70. Seed T, Kumar S, Whitnall M, Srinivasan V, Singh V, Elliott T, Landauer M, Miller A, Chang C-M, Inal C, Deen J, Gehlhaus M, Jackson W, Hilyard E, Pendergrass J, Toles R, Villa V, Miner V, Steward M, Benjack J, Danilenko D, Farrell C. New strategies for the prevention and treatment of riadiation injury: possible implications for countering radiation hazards of long-term space travel. J Radiat Res 43(Suppl):S239-S244, 2002c.
71. Seed TM, Inal CE, Whitnall MH, Kumar KS, Srinivasan V, Pendergrass JA, Villa VO, Miner VL. Developing efficacy and safety profiles for 5-androstenediol. In: Proceedings of the 12th International Congress of Radiation Research. Lucus Heights, AU: Australian Institute of Nuclear Science and Engineering; ICRR-2003; 2003: 393.
72. Shaw L, Brown W, Schein P, Stogniew M. A phase 1 study comparing the relative bioavailability of intravenous (IV) and subcutaneous (SC) administration of Amifostine (Ethyol®). Clinical Pharmacol 883; 1998.
73. Shimoi K, Masuda S, Shen B, Furugori M, Kinae N. Radioprotective effects of antioxidative plant flavonoids in mice. Mutat Res 350:153-161; 1996.
74. Singh VJ, Seed TM. Radiation effects. In: Roy MJ, ed. Physician's guide to terrorist attack radiation effects. Totowa, NJ: Humana Press; 2003: 339-362.
75. Singh VK, Seed TM, Kumar KS. N-palmitoylation of the radioprotective domain of interleukin-1 affords inhibition of LPS-induced nitric oxide generation. Immunopharmacol Immunotoxicol 26:193-202; 2004.
76. Singh VK, Srinivasan V, Seed TM, Jackson WE, Miner VE, Kumar KS. Radioprotection by N-palmitoylated nonapeptide of human interleukin-1beta. Peptides 26:413-418; 2005.
77. Srinivasan V, Weiss JF, Kumar KS. Radioprotection by combinations of WR-151327, vitamin E and selenomethionine. In: Proceedings of the 40th Annual Meeting of the Radiation Research Society. Salt Lake City, UT: RRS; 1992: 26.
78. Srinivasan V, Pendergrass JA, Kumar KS, Landauer MR, Seed TM. Radioprotection, pharmacokinetic, and behavioral studies in mice implanted with biodegradable drug (Amifostine) pellets. Int J Radiat Biol 78:535-543; 2002.
79. Steel-Goodwin L, Egan JE, Kendrick JM, Jackson W, Herman-Ackah LM, Eckstein JM. Comparative intestinal and testes toxicity of four aminothiols in irradiated and non-irradiated mice. Ann Clin Lab Sci 23:439-447; 1993.
80. Stone HB, Moulder JE, Coleman CN, Ang KK, Anscher MS, Barcellos-Hoff MH, Dynan WS, Fike JR, Grdina DJ, Greenberger JS, Hauer-Jensen M, Hill RP, Kolesnick RN, Macvittie TJ, Marks C, McBride WH, Metting N, Pellmar T, Purucker M, Robbins ME, Schiestl RH, Seed TM, Tomaszewski JE, Travis EL, Wallner PE, Wolpert M, Zaharevitz D. Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI workshop. Radiat Res 162:711-728; 2004.
81. Thorstad WL, Haughey B, Chao KS. Pilot study of subcutaneous Amifostine in patients undergoing postoperative: intensity modulated radiation therapy for head and neck cancer: preliminary data. Semin Oncol 30(Suppl 18):96-100; 2003.
82. Turnbull JL, Patchen ML, Scadden DT. The polysaccharide, PGG-glucan, enhances human myelopoiesis by direct action independent of and additive to early-acting cytokines. Acta Haematol 102:66-71; 1999.
83. U.S. Food and Drug Administration/Center for Drug Evaluation and Research [online]. Rockville, MD: U.S. FDA; 2003. Available at: http://www.fda.gov/cder/ regulatory/ applications. Accessed 24 May 2005.
84. U.S. Food and Drug Administration. 21 CFR Parts 314 and 601-Developing drugs for prevention of toxicity of chemical, biological, radiological or nuclear substances, final rule. Washington, DC: U.S. Government Printing Office-Federal Register; 31 May 2002.
85. U.S. Nuclear Regulatory Commission. Consideration of potassium iodide in emergency plans. Washington, DC: U.S. Government Printing Office; Final rule. 66 Federal Register 5427-5440; 2001.
86. Van der Vijgh WJ, Peters GJ. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by Amifostine (Ethyol): preclinical aspects. Semin Oncol 21(Suppl 11):2-7; 1994.
87. Wakselman C. Fluorinated organic compounds: synthesis and biological applications. Ann Parma Fr 57:108-115; 1999.
88. Walker RI. Requirements of radioprotectors for military and emergency needs. Pharmacol Ther 39:13-20; 1988.
89. Waselenko JK, MacVittie TJ, Blakely WF, Pesik N, Wiley AL, Dickerson WE, Tsu H, Confer DL, Coleman CN, Seed T, Lowry P, Armitage JO, Dainiak N. Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med 140:1037-1051; 2004.
90. Weiss JF. Pharmacologic approaches to protection against radiation-induced lethality and other damage. Environ Health Perspect 105(Suppl 6):1473-1478; 1997.
91. Weiss JF, Landauer MR. Radioprotection by antioxidants. Ann N Y Acad Sci 899:44-60; 2000.
92. Weiss JF, Landauer MR. Protection against ionizing radiation by antioxidant nutrients and phytochemicals. Toxicol 189:1-20; 2003.
93. Weiss J, Kumar KS, Srinivasan V, Landauer MR. Comparison of toxicity and radioprotective efficacy of WR-2721 and WR-3689 in mice. Proc Am Assoc Can Res 31:433; 1990.
94. Weiss JF, Srinivasan V, Kumar KS, Landauer MR. Radioprotection by metal: selenium. Adv Space Res 12:223-231; 1992.
95. Whitnall MH, Elliott TB, Harding RA, Inal CE, Landauer MR, Wilhelmsen CL, McKinney L, Miner VL, Jackson WE III, Loria RM, Ledney GD, Seed TM. Androstenediol stimulates myelopoiesis and enhances resistance to infection in gamma-irradiated mice. Int J Immunopharm 22:1-14; 2000.
96. Whitnall MH, Inal CE, Jackson WE, Miner VL, Villa V, Seed TM. In vivo radioprotection by 5-androstenediol: stimulation of the innate immune system. Radiation Res 156:283-293; 2001.
97. Whitnall MH, Elliott TB, Landauer MR, Wilhelmsen CL, McKinney L, Kumar KS, Srinivasan V, Ledney GD, Seed TM. Protection against gamma-irradiation with 5-androstenediol. Mil Med 167:64-65; 2002a.
98. Whitnall MH, Wilhelmsen CL, McKinney L, Miner V, Seed TM, Jackson WE III. Radioprotective efficacy and acute toxicity of 5-androstenediol after subcutaneous or oral administration in mice. Immunopharm Immunotox 24:595-626; 2002b.
99. Yi ES, Williams ST, Lee H, Malicki DM, Chin EM, Yin S, Tarpley J, Ulich TR. Keratinocyte growth factor ameliorates radiation- and bleomycin-induced lung injury and mortality. Am J Pathol 149:1963-1970; 1996.